REGENXBIO (RGNX) IPO Prices In-Line at $22
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
REGENXBIO Announces Pricing of Initial Public Offering
September 16, 2015 8:30 PM EDTROCKVILLE, Md., Sept. 16, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. ("REGENXBIO"), a leading biotechnology company in gene therapy, today announced the pricing of its initial public offering of 6,300,000 shares of its common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions. In addition, REGENXBIO granted the underwriters a 30-day option to purchase up to an additional 945,000 shares of its common stock at the same price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on September 17, 2015 under the ticker symbol "RGNX."
Morgan Stanley and BofA Merrill Lynch are acting as active joint... More



